Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Urine mRNA to identify a novel pseudoexon causing dystrophinopathy.

Antoury L, Hu N, Darras B, Wheeler TM.

Ann Clin Transl Neurol. 2019 May 17;6(6):1106-1112. doi: 10.1002/acn3.777. eCollection 2019 Jun.

2.

Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting.

Kench JG, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Egevad L.

Virchows Arch. 2019 May 16. doi: 10.1007/s00428-019-02574-0. [Epub ahead of print] Review.

PMID:
31098802
3.

Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1.

Hu N, Antoury L, Baran TM, Mitra S, Bennett CF, Rigo F, Foster TH, Wheeler TM.

Nat Commun. 2018 Dec 7;9(1):5227. doi: 10.1038/s41467-018-07517-y.

4.

Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG.

Pathology. 2019 Jan;51(1):11-20. doi: 10.1016/j.pathol.2018.10.003. Epub 2018 Nov 23.

PMID:
30477882
5.

Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies.

Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM.

Nat Commun. 2018 Sep 25;9(1):3906. doi: 10.1038/s41467-018-06206-0.

6.

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

Lee HS, Jang HJ, Choi JM, Zhang J, de Rosen VL, Wheeler TM, Lee JS, Tu T, Jindra PT, Kerman RH, Jung SY, Kheradmand F, Sugarbaker DJ, Burt BM.

JCI Insight. 2018 Apr 5;3(7). pii: 98575. doi: 10.1172/jci.insight.98575. eCollection 2018 Apr 5.

7.

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.

Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ.

Ann Thorac Surg. 2017 Nov;104(5):1679-1687. doi: 10.1016/j.athoracsur.2017.06.042. Epub 2017 Sep 28.

PMID:
28964420
8.

Editorial Comment.

Wheeler TM.

J Urol. 2017 Dec;198(6):1323. doi: 10.1016/j.juro.2017.05.103. Epub 2017 Sep 5. No abstract available.

PMID:
28886350
9.

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.

Jauvin D, Chrétien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, MacLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J.

Mol Ther Nucleic Acids. 2017 Jun 16;7:465-474. doi: 10.1016/j.omtn.2017.05.007. Epub 2017 May 17.

10.

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.

Wang DH, Lee HS, Yoon D, Berry G, Wheeler TM, Sugarbaker DJ, Kheradmand F, Engleman E, Burt BM.

Clin Cancer Res. 2017 Feb 1;23(3):778-788. doi: 10.1158/1078-0432.CCR-15-2597. Epub 2016 Aug 5.

11.

Morphometric analysis of calcification and fibrous layer thickness in carotid endarterectomy tissues.

Han RI, Wheeler TM, Lumsden AB, Reardon MJ, Lawrie GM, Grande-Allen KJ, Morrisett JD, Brunner G.

Comput Biol Med. 2016 Mar 1;70:210-219. doi: 10.1016/j.compbiomed.2016.01.019. Epub 2016 Jan 22.

12.

An Innovative Interactive Modeling Tool to Analyze Scenario-Based Physician Workforce Supply and Demand.

Gupta S, Black-Schaffer WS, Crawford JM, Gross D, Karcher DS, Kaufman J, Knapman D, Prystowsky MB, Wheeler TM, Bean S, Kumar P, Sharma R, Chamoli V, Ghai V, Gogia V, Weintraub S, Cohen MB, Robboy SJ.

Acad Pathol. 2015 Oct 13;2(4):2374289515606730. doi: 10.1177/2374289515606730. eCollection 2015 Oct-Dec.

13.

Case Records of the Massachusetts General Hospital. Case 30-2015: A 50-Year-Old Man with Cardiogenic Shock.

Wheeler TM, Baker JN, Chad DA, Zilinski JL, Verzosa S, Mordes DA.

N Engl J Med. 2015 Sep 24;373(13):1251-61. doi: 10.1056/NEJMcpc1415169.

PMID:
26398074
14.

Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.

Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, Gattis D, Jauvin D, Puymirat J, Swayze EE, Freier SM, Bennett CF, Thornton CA, MacLeod AR.

J Pharmacol Exp Ther. 2015 Nov;355(2):329-40. doi: 10.1124/jpet.115.226969. Epub 2015 Sep 1.

15.

Active surveillance for prostate cancer: the role of the pathologist.

Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB.

Pathology. 2015 Jan;47(1):1-3. doi: 10.1097/PAT.0000000000000186. No abstract available.

PMID:
25474525
16.

Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist.

Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB; College of American Pathologists; International Society of Urological Pathology; Association of Directors of Anatomic and Surgical Pathology.

Virchows Arch. 2014 Dec;465(6):623-8. doi: 10.1007/s00428-014-1668-5. Epub 2014 Oct 16.

PMID:
25316188
17.

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.

PMID:
25263387
18.

Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy.

von Rundstedt FC, Lerner SP, Godoy G, Amiel G, Wheeler TM, Truong LD, Shen SS.

J Urol. 2015 Jan;193(1):58-63. doi: 10.1016/j.juro.2014.07.114. Epub 2014 Aug 12.

19.

The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.

Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME.

Arch Pathol Lab Med. 2014 Oct;138(10):1387-405. doi: 10.5858/arpa.2014-0219-SA. Epub 2014 Aug 5. Review.

PMID:
25092589
20.

Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis.

San Martin R, Barron DA, Tuxhorn JA, Ressler SJ, Hayward SW, Shen X, Laucirica R, Wheeler TM, Gutierrez C, Ayala GE, Ittmann M, Rowley DR.

Am J Pathol. 2014 Jun;184(6):1860-70. doi: 10.1016/j.ajpath.2014.02.021. Epub 2014 Apr 5.

21.

Splicing biomarkers of disease severity in myotonic dystrophy.

Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT 3rd, Thornton CA.

Ann Neurol. 2013 Dec;74(6):862-72. doi: 10.1002/ana.23992.

22.

Metabolomic signatures of aggressive prostate cancer.

McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, Lotan Y, Wheeler TM.

Prostate. 2013 Oct;73(14):1547-60. doi: 10.1002/pros.22704. Epub 2013 Jul 3.

23.

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.

Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG.

Invest New Drugs. 2014 Apr;32(2):235-242. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.

24.

Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.

Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, Wheeler TM, Schlossberg S, Penson DF, Taneja SS.

J Urol. 2013 Jun;189(6):2039-46. doi: 10.1016/j.juro.2013.02.072. Epub 2013 Feb 26. Review.

25.

Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.

Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Wernert N, Perner S, Freedland SJ, Corman JM, Ittmann MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G.

J Mol Diagn. 2013 Mar;15(2):270-9. doi: 10.1016/j.jmoldx.2012.11.002. Epub 2012 Dec 22.

26.

Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting.

Kench JG, Delahunt B, Griffiths DF, Humphrey PA, McGowan T, Trpkov K, Varma M, Wheeler TM, Srigley JR.

Histopathology. 2013 Jan;62(2):203-18. doi: 10.1111/his.12042. Review.

PMID:
23240714
27.

RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.

Sobczak K, Wheeler TM, Wang W, Thornton CA.

Mol Ther. 2013 Feb;21(2):380-7. doi: 10.1038/mt.2012.222. Epub 2012 Nov 27.

28.

Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?

Bonkhoff H, Wheeler TM, van der Kwast TH, Magi-Galluzzi C, Montironi R, Cohen RJ.

Prostate. 2013 Mar;73(4):442-8. doi: 10.1002/pros.22579. Epub 2012 Sep 4. Review.

PMID:
22949099
29.

Targeting nuclear RNA for in vivo correction of myotonic dystrophy.

Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA.

Nature. 2012 Aug 2;488(7409):111-5. doi: 10.1038/nature11362.

30.

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI.

Am J Surg Pathol. 2012 Sep;36(9):1346-52. doi: 10.1097/PAS.0b013e3182556dcd.

31.

Pseudolumen size and perimeter in prostate cancer: correlation with patient outcome.

Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, Lucia MS.

Prostate Cancer. 2011;2011:693853. doi: 10.1155/2011/693853. Epub 2011 Jul 14.

32.

Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.

Mankodi A, Wheeler TM, Shetty R, Salceies KM, Becher MW, Thornton CA.

Neurobiol Dis. 2012 Jan;45(1):539-46. doi: 10.1016/j.nbd.2011.09.010. Epub 2011 Sep 21.

33.

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.

Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D.

Clin Cancer Res. 2011 Nov 15;17(22):7174-82. doi: 10.1158/1078-0432.CCR-11-1899. Epub 2011 Sep 20.

34.

Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, La Rosa FG, Cook S, Werahera PN, Lucia MS.

Am J Clin Pathol. 2011 Jul;136(1):98-107. doi: 10.1309/AJCPZ7WBU9YXSJPE.

35.

Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.

Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ.

BJU Int. 2011 Oct;108(7):1074-85. doi: 10.1111/j.1464-410X.2010.10039.x. Epub 2011 Apr 13. Review.

36.

Desquamating apoptotic variant of high-grade prostatic intraepithelial neoplasia: a possible precursor of intraductal prostatic carcinoma.

Cohen RJ, O'Brien BA, Wheeler TM.

Hum Pathol. 2011 Jun;42(6):892-5. doi: 10.1016/j.humpath.2010.09.008. Epub 2011 Feb 1.

PMID:
21288556
37.

Ductal adenocarcinoma of the prostate.

Cohen RJ, O'Brien BA, Wheeler TM.

Hum Pathol. 2011 Apr;42(4):605-6; author reply 606-7. doi: 10.1016/j.humpath.2010.07.025. Epub 2011 Jan 15. No abstract available.

PMID:
21237485
38.

Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.

Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR.

Am J Pathol. 2011 Jan;178(1):79-87. doi: 10.1016/j.ajpath.2010.09.042. Epub 2010 Dec 23.

39.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.

Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group.

Mod Pathol. 2011 Jan;24(1):6-15. doi: 10.1038/modpathol.2010.178. Epub 2010 Sep 10. Review.

40.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes.

Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; ISUP Prostate Cancer Group.

Mod Pathol. 2011 Jan;24(1):39-47. doi: 10.1038/modpathol.2010.160. Epub 2010 Sep 3. Review.

41.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.

van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group.

Mod Pathol. 2011 Jan;24(1):16-25. doi: 10.1038/modpathol.2010.156. Epub 2010 Sep 3. Review.

42.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease.

Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer Group.

Mod Pathol. 2011 Jan;24(1):26-38. doi: 10.1038/modpathol.2010.158. Epub 2010 Aug 27. Review.

43.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins.

Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group.

Mod Pathol. 2011 Jan;24(1):48-57. doi: 10.1038/modpathol.2010.155. Epub 2010 Aug 20.

44.

A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis.

O'Brien BA, Cohen RJ, Wheeler TM, Moorin RE.

BJU Int. 2011 Feb;107(3):389-95. doi: 10.1111/j.1464-410X.2010.09539.x. Epub 2010 Aug 12. Review.

45.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E.

J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012. Epub 2010 May 15.

PMID:
20478579
46.

Taking DNA from the dead.

McGuire AL, Majumder MA, Halpern SD, Swindell JS, Yaeger LV, Gibbs RA, Wheeler TM.

Nat Rev Genet. 2010 May;11(5):318. doi: 10.1038/nrg2792. Epub 2010 Mar 23. No abstract available.

47.

Protocol for the examination of specimens from patients with carcinoma of the prostate gland.

Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2009 Oct;133(10):1568-76. doi: 10.1043/1543-2165-133.10.1568. No abstract available.

PMID:
19792046
48.

Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13915-20. doi: 10.1073/pnas.0905780106. Epub 2009 Aug 10.

49.

Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA.

Science. 2009 Jul 17;325(5938):336-9. doi: 10.1126/science.1173110.

50.

Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer.

Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, Ayala GE.

Anticancer Res. 2009 Jun;29(6):2077-81.

Supplemental Content

Loading ...
Support Center